[go: up one dir, main page]

WO2002053139A3 - Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders - Google Patents

Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders Download PDF

Info

Publication number
WO2002053139A3
WO2002053139A3 PCT/US2001/045863 US0145863W WO02053139A3 WO 2002053139 A3 WO2002053139 A3 WO 2002053139A3 US 0145863 W US0145863 W US 0145863W WO 02053139 A3 WO02053139 A3 WO 02053139A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonist
treatment
amino acid
excitatory amino
neurological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/045863
Other languages
French (fr)
Other versions
WO2002053139A8 (en
WO2002053139A2 (en
Inventor
Kirk Willis Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU2002241565A priority Critical patent/AU2002241565A1/en
Publication of WO2002053139A2 publication Critical patent/WO2002053139A2/en
Publication of WO2002053139A3 publication Critical patent/WO2002053139A3/en
Anticipated expiration legal-status Critical
Publication of WO2002053139A8 publication Critical patent/WO2002053139A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method of treating a neurological disorder, particularly migraine, comprising administering to a patient an effective amount of an excitatory amino receptor antagonist in combination with a 5HT1f agonist.
PCT/US2001/045863 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders Ceased WO2002053139A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002241565A AU2002241565A1 (en) 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25992301P 2001-01-05 2001-01-05
US60/259,923 2001-01-05

Publications (3)

Publication Number Publication Date
WO2002053139A2 WO2002053139A2 (en) 2002-07-11
WO2002053139A3 true WO2002053139A3 (en) 2002-08-22
WO2002053139A8 WO2002053139A8 (en) 2003-11-13

Family

ID=22987001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045863 Ceased WO2002053139A2 (en) 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Country Status (2)

Country Link
AU (1) AU2002241565A1 (en)
WO (1) WO2002053139A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627328B1 (en) 2010-10-15 2016-09-14 Contera Pharma APS Combinations of serotonin receptor agonists for treatment of movement disorders
HUE037732T2 (en) 2012-04-18 2018-09-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP3481385B1 (en) 2016-07-11 2025-09-03 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721252A (en) * 1994-10-05 1998-02-24 Eli Lilly And Company 5HT1F agonists for the treatment of migraine
WO1998045270A1 (en) * 1997-04-07 1998-10-15 Eli Lilly And Company Pharmacological agents
WO2001001972A2 (en) * 1999-07-06 2001-01-11 Eli Lilly And Company SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721252A (en) * 1994-10-05 1998-02-24 Eli Lilly And Company 5HT1F agonists for the treatment of migraine
WO1998045270A1 (en) * 1997-04-07 1998-10-15 Eli Lilly And Company Pharmacological agents
WO2001001972A2 (en) * 1999-07-06 2001-01-11 Eli Lilly And Company SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Also Published As

Publication number Publication date
WO2002053139A8 (en) 2003-11-13
AU2002241565A1 (en) 2002-07-16
WO2002053139A2 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
WO2002032374A3 (en) Methods for treating il-18 mediated disorders
MXPA02001306A (en) Pharmaceutical compositions for the treatment of cns and other discorders.
EP0900568A3 (en) AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
WO2003096983A3 (en) Method of treating dyslipidemic disorders
EP1471909A4 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
WO2002098370A3 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2005107726A3 (en) Method for the treatment of back pain
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2002097033A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
WO2004024150A3 (en) Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
AU2003296341A8 (en) System and method for treating Parkinson's Disease and other movement disorders
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2004064766A3 (en) Method of treatment of conditions by administration of streptolysin o
WO2003015690A3 (en) Method for treating primary insomnia
WO2002053139A3 (en) Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 28/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 28/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP